In order to discuss and establish a joint position on the treatment of low serum levels of high-density lipoprotein cholesterol (HDL-C), a group of experts involved in the care of people with dyslipidaemia and at risk of cardiovascular disease met in Miami, Florida, US, on 5th and 6th March 2005. The experts came from the Latin American countries Argentina, Brazil, Chile, Colombia, Ecuador, Guatemala, Mexico and Venezuela and had at least five years of experience in the care of patients with dyslipidaemia and low HDL-C.
The main objective of the meeting was to discuss and propose a treatment for low serum HDL-C levels as a cardiovascular risk factor in patients and to create a group of useful recommendations in this regard, applicable to the daily clinical practice of physicians dealing with patients with dyslipidaemia and cardiovascular disease.
This document describes the methodology developed to obtain these recommendations and presents the results of this academic meeting.
References
1.
1. Yusuf S, Reddy S, Ounpuu S et al.Global burden of cardiovascular disease: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation2001;104:2746–53.
2.
2. Rabelo LM, Viana RM, Schimith MA et al.Risk factors for atherosclerosis in students of a private university in São Paulo — Brazil. Arq Bras Cardiol1999;72:575–80.
3.
3. Chiang-Salgado MT, Casanueva V, Escobar MC et al.Factores de riesgo cardiovascular en estudiantes universitarios chilenos. Revista Salud Pública Méx1999;41:444–51.
4.
4. Bianchi M, Fernández Cean J, Carbonell E et al.Encuesta epidemiológica de hipertensión arterial en Montevideo. Prevalencia, factores de riesgo, plan de seguimiento. Rev Med Uruguay1994;10:113–20.
5.
5. Fernández Antunes A.Epidemiología de la hipertensión arterial en la población adulta de la ciudad de Paysandú, Uruguay. Rev Med Paysandú1985;2:18–40.
6.
6. Liga Uruguaya contra la Hipertensión Arterial.Segundo Consenso Uruguayo de HTA. Rev Hipertensión Arterial2000;7:5–8.
7.
7. Obesidad, patogenia, clínica y tratamiento. Ed. J Braguinsky et al. Buenos Aires: El Ateneo, 1997.
8.
8. Nigro D, Vergonttini JC, Kuschnir E et al.Epidemiologia de la hipertensión arterial en la ciudad de Córdoba. Rev Fed Arg Cardiol1999;28:69–75.
9.
9. Gus I, Gus M, Fischmann A, Medina C. Prevalencia de hipertensión arterial sistémica en Rio Grande do Sul y factores de riesgo asociados. Segundo congreso virtual de Cardiología. SBC www.cardiol.br [Prevalence of systemic hypertension in rio Grande do Sul and associated risk factors. Second virtual congress of Cardiology].
10.
10. Encuesta Nacional de Salud 2000, Instituto Nacional de Salud Pública México [National Health Survey 2000, Mexican National Institute of Public Health]. Available at URL www.insp.mx/ensa/ensa_tomo2.pdf
11.
11. Primera Encuesta Nacional de Salud. Documento MINSAL 2003 [First National Health Survey. MINSAL Document]. Available at URL: http://www.minsal.cl/depots/saludpublica/ResultadoEncuestaNacional.html
12.
12. Jadue L, Vega J, Escobar MC, Delgado B.Risk factors for chronic non-communicable diseases: methods and results of CARMEN program basal survey. Rev Med Chil Nutr1999;127:1004–39.
13.
13. Braguinsky J. Prevalencia de obesidad en América latina. Available URL www.cfnavarra.es/salud/anales/textos/vol25/supl1/suple11a.html
14.
14. Monteiro CA, D'A Benicio MH, Conde WL et al.Shifting obesity trends in Brazil. Eur J Clin Nutr2000;54:342–6.
15.
15. Sichieri R, Coitinho DC, Leao MM et al.High temporal, geographic and income variation in body mass index among adults in Brazil. Am J Public Health1994;84:793–8.
16.
16. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NECP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (ATP III). JAMA2001;285:2486–97.
17.
17. Resano-Perez E, Mendez-Ramirez I, Shamah-Levy T et al.Second National Nutrition Survey. 1999. Salud Publica Mex2003;45(suppl 4): S477–89.
18.
18. Ministerio de Salud y Ambiente de la Nación. Unidad de Análisis y Monitoreo de la Salud Argentina. Boletín Epidemiológico Periódico, 2004 [Unit for the analysis and monitoring of Argentinian health]. Available URL: http.//www.direpi.vigia.gov.ar
19.
19. Litwak LE, Graffigna MN, Abdala MM et al.Prevalencia de factores de riesgo cardiovascular en sujetos presuntamente sanos. Estudio epidemiológico multicéntrico (resultados preliminares). Rev Argent Endocrinol Metabol2004:9:41.
20.
20. Campos G, Ryder E, Diez Ewald M et al.Prevalencia de obesidad e hiperinsulinemia en una población aparentemente sana de Maracaibo, Venezuela y su relación con las concentraciones de lípidos y lipoproteínas del suero. Invest Clín2003;44(1):1–24.
21.
21. Jacoby E, Bull F, Neiman A.Cambios acelerados del estilo de vida obligan a fomentar la actividad física como prioridad en la región de las Américas. Rev Panam Salud Publica2003;14:223–5.
22.
22. Seclén-Palacín JA, Jacoby ER.Factores sociodemográficos y ambientales asociados con la actividad física deportiva en la población urbana del Perú. Rev Panam Salud Publica2003;14:255–64.
23.
23. Novotny TE, Nicholls ES, Restrepo H.Tabaco o salud: situación en las Américas, in Special report. Bol Sanit Panam1992;113:281–9.
24.
24. SSA/CONADIC 2000. Programa Nacional Contra las Adicciones. Programa Contra el Tabaquismo. Secretaria de Salud — Consejo Nacional Contra las Adicciones México, D.F. México [National Program Against Adictions. Anti-Smoking Program. Secretary of Health — National Council Against Adictions] México, D.F. México, p1–110.
25.
25. Secretaría Nacional de Prevención del Uso Indebido de Drogas. Estudio nacional sobre consumo de sustancias adictivas en la República Argentina. Buenos Aires, Argentina [Natational Secretariat for the Prevention of Drug Abuse. National study on the consumption of addictive substances in the Republic of Argentina], Buenos Aires, Argentina, 1999.
26.
26. Gordon T, Castelli WP, Hjortland MC et al.High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med1977;62:707–14.
27.
27. Assmann G, Schulte H, von Eckardstein A et al.High density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PRO-CAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis1996;124(suppl):S11–S20.
28.
28. International Atherosclerosis Society. Harmonized clinical guidelines on prevention of atherosclerotic vascular disease. http.//www.athero.org
29.
29. Gordon DJ, Probsfield JL, Garrison RJ et al.High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation1989;79:8–15.
30.
30. Pearson TA, Bulkley BH, Achuff SC et al.The association of low levels of HDL cholesterol and arteriographically defined artery disease. Am J Epidemiol1979;109:285–95.
31.
31. Aguilar-Salinas CA, Olaiz G, Valles V et al.High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res2001;42:1298–307.
32.
32. Health Survey for England 1998; cardiovascular disease, http.//www. doh.gov.uk/Publications and Statistics/Published Survey/Health Survey for England/Health Survey Results/fs/en.
33.
33. Downs JR, Clearfield M, Weis S et al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA1998;279:1615–22.
34.
34. Ballantyne CM, Olsson AG, Cook TJ et al.Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation2001;104:3046–51.
35.
35. Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. A randomized placebo-controlled trial. Lancet2002;360:7–22.
36.
36. Shepherd J, Cobbe SM, Ford I et al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, West of Scotland Coronary Prevention Study Group. N Engl J Med1995;333:1301–07.
37.
37. Rubins HB, Robins J, Collins D et al.Effect of a fibrate on lipid profiles in the VA-HIT study at 5 years. N Engl J Med1999;341:410–18.
38.
38. Canner PL, Berge KG, Wenger NK et al.Research Group. Fifteen year mortality in Coronary Drug Project. Patients' long term benefit with Niacin. Results from secondary prevention study. Coronary Drug Project. J Am Coll Cardiol1986;8:1245–55.
39.
39. Ballantyne CM, Herd JA, Ferlic LL et al.Influence of HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation1999;99:736–43.
40.
40. Shepherd J.Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J1995;16:5–13.
41.
41. Kraus WE, Houmard JA, Duscha BD et al.Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med2002;347:1483–92.
42.
42. Manninen V, Elo MO, Frick MH et al.Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA1988;260:641–51.
43.
43. McKenney J.New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med2004;164:697–705.
44.
44. Calabresi L, Gomaraschi M, Franceshini G.Endothelial protection by high-density lipoproteins. Arterioscler Thromb Vasc Biol2003;23:1724–31.
45.
45. Brown BG, Zhao XQ, Chait A et al.Nicotinic acid lead to atherosclerotic regression : HATS study. N Engl J Med2001;345:1583–92.
46.
46. Jungnickel PN, Maloley PA, Vander-Tuln EL et al.Effect of two aspirin pretreatment regimens on niacin induced cutaneous reactions. J Gen Intern Med1997;12:591–6.
47.
47. Salkind NJ.Exploring research. Likert scales. 3th ed. Prentice Hall Inc. A Simon & Schuster Company. Kansas City, North Carolina, USA, 1998.
48.
48. Taylor AJ, Sullenberger LE, Lee HJ et al.Inhibition of atherosclerosis in the ARBITER 2 study. Circulation2004;110:3512–17.
50. Elam MB, Hunninghake DB, Davis KB et al.Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: a randomized trial. JAMA2000;284:1263–70.
51.
51. Grundy SM, Vega GL, Mc Govern ME et al.Efficacy and safety, and tolerability of one-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Results of the Assessment of Diabetes Control and Evaluation of the efficacy of Niaspan Trial. Arch Intern Med2002;162:1568–76.
